# FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

> **NCT06669117** · PHASE1,PHASE2 · RECRUITING · sponsor: **Pierre Fabre Medicament** · enrollment: 140 (estimated)

## Conditions studied

- Solid Tumor
- MET Alteration

## Interventions

- **DRUG:** VERT-002

## Key facts

- **NCT ID:** NCT06669117
- **Lead sponsor:** Pierre Fabre Medicament
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-22
- **Primary completion:** 2030-10-21
- **Final completion:** 2032-10-01
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2025-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06669117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06669117, "FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06669117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*